All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Roswell Park Care Network Expands with New Thoracic Surgery Services and Faculty

September 26th 2025

Five new faculty members join network; three at St. Joseph’s Health in Syracuse as it launches new services.

Revumenib Joins NCCN Guidelines for NPM1-Mutated R/R Acute Myeloid Leukemia

September 26th 2025

The NCCN has issued a category 2A recommendation for revumenib in relapsed/refractory acute myeloid leukemia harboring an NPM1 mutation.

Stenoparib Monotherapy Yields Potential OS Benefit in Platinum-Resistant Ovarian Cancer

September 26th 2025

Stenoparib monotherapy generated long-term clinical benefit in patients with platinum-resistant and -refractory advanced ovarian cancer.

Sunvozertinib Approval Fills Treatment Gap in Pretreated EGFR Exon 20–Mutant NSCLC

September 26th 2025

Lyudmila A. Bazhenova, MD, discusses the FDA approval of sunvozertinib (Zegfrovy) in patients with EGFR exon 20–mutant non–small cell lung cancer.

Pirtobrutinib Offers Potential Second-Line Treatment in CLL

September 26th 2025

Jennifer A. Woyach, MD, discusses the potential of pirtobrutinib as a second-line option for patients with CLL.

KITE-363 Shows Potential As a Next-Generation CAR T-Cell Therapy for R/R LBCL

September 26th 2025

Saurabh Dahiya, MD, FACP, discussed how the unique mechanism of action of KITE-363 may improve upon the efficacy of other CAR T-cell therapies for LBCL.

FDA Removes REMS Program for Vandetanib for Medullary Thyroid Cancer

September 25th 2025

The FDA has removed the REMS program for vandetanib for the treatment of patients with medullary thyroid cancer.

First-Line Atebimetinib Plus mGnP Yields High 9-Month OS Rate in Pancreatic Cancer

September 25th 2025

Atebimetinib plus modified gemcitabine/nab-paclitaxel continued to elicit high OS rates in patients with treatment-naive pancreatic cancer.

FDA Approves Imlunestrant for ER+, HER2-Negative, ESR1-Mutated Metastatic Breast Cancer

September 25th 2025

The FDA approved imlunestrant for ER-positive, HER2-negative advanced or metastatic ESR1-mutated breast cancer following endocrine therapy.

Mitazalimab Plus Chemo Demonstrates Potential OS Benefit in Previously Untreated Metastatic Pancreatic Cancer

September 25th 2025

Mitazalimab plus mFOLFIRINOX demonstrated encouraging survival outcomes in previously untreated metastatic pancreatic cancer.

Dana-Farber Cancer Institute and Northeastern University Partner to Train the Next Generation of Clinical-Ready Oncology Nurses

September 25th 2025

Through a new agreement, nurse scientists from Dana-Farber will become Northeastern faculty members, bringing oncology nursing science into the classroom.

A400/EP0031 NDA Accepted for Review in China for RET Fusion–Positive NSCLC

September 25th 2025

China’s NMPA has accepted for review a new drug application for A400/EP0031 in patients with RET fusion–positive non–small cell lung cancer.

FDA Grants Utidelone Injection Orphan Drug Designation for Pancreatic Cancer

September 25th 2025

Utidelone injection has received orphan drug designation by the FDA for the treatment of patients with pancreatic cancer.

Avantect Multi-Cancer and Ovarian Cancer Detection Tests Achieve UKCA Marking

September 25th 2025

A United Kingdom Conformity Assessed marking was granted to the Avantect Multi-Cancer Detection Test and Avantect Ovarian Cancer Test.

Zanubrutinib Shows Superior PFS vs Venetoclax/Obinutuzumab in Indirect Comparison of Treatment-Naive CLL

September 25th 2025

An indirect comparison of SEQUOIA and CLL14 shows zanubrutinib improved PFS over venetoclax/obinutuzumab in treatment-naive CLL after baseline adjustment.

Breast Cancer Experts: Key ADC Developments and CDK 4/6 Inhibitor Updates Set to Dominate ESMO 2025

September 25th 2025

Ahead of the 2025 ESMO Congress, breast cancer experts share the most anticipated research being presented during the meeting.

Timing of Real-World Belzutifan-Related AEs Varies Between VHL-Associated Tumors and Sporadic RCC

September 25th 2025

Real-world data highlighted differences in the timing and severity of belzutifan-related toxicities in VHL-associated tumors and sporadic RCC.

Dostarlimab Plus Chemo Expands Frontline Options in Advanced/Recurrent Endometrial Cancer

September 24th 2025

Dana M. Chase, MD, discusses the effect of the frontline dostarlimab plus chemotherapy on the recurrent endometrial cancer landscape.

SCOPE Score Validated as Predictive Tool for Outcomes With BCMA CAR T-Cell Therapy in R/R Multiple Myeloma

September 24th 2025

The SCOPE score was predictive of response, toxicity, and survival outcomes in patients with relapsed/refractory myeloma receiving BCMA CAR T-cell therapy.

FDA Grants Fast Track Designation to Alnodesertib Plus Irinotecan in ATM-Negative mCRC

September 24th 2025

Alnodesertib has received fast track designation from the FDA for patients with ATM-negative metastatic colorectal cancer.